Glutide for Ending Methamphetamine

NCT07204249 on ClinicalTrials.gov · last registry update 2026-06-03

Recruiting now, toward 162 participants. Due to report 15 February 2030, alongside 7 other tracked readouts that quarter. Primary outcome, as filed: Ratio of eligible to enrolled participants. Sponsors move these dates routinely; any movement since this site started watching is listed below. semaglutide is approved in the US, but not for substance use — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: RECRUITING
Phase: P2
Drug: semaglutide
Ozempic, Rybelsus, Wegovy
Sponsor: San Francisco Department of Public Health
Sponsor type: Other Gov
Enrollment: 162
Started: 2026-02-26
Primary completion: 2030-02-15 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Ratio of eligible to enrolled participants

Conditions studied

Methamphetamine-dependence

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.